Rapid-Acting Insulin Now Approved for Use With Pumps

| Mar 1, 2002

NovoLog (insulin aspart) has received supplemental approval from the U.S. Food and Drug Administration for use in external insulin pumps, Novo Nordisk Pharmaceuticals announced in December 2001. This decision, according to Novo Nordisk, makes NovoLog the only rapid-acting insulin analog to be indicated for use with pumps.

Eli Lilly tells Diabetes Health that it expects FDA approval for Humalog use in pumps later this year.

Click Here To View Or Post Comments

Categories: Diabetes, Diabetes, Food, Health Insurance, Insulin, Insulin Pumps, Novo Nordisk

Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Top Rated
Print | Email | Share | Comments (0)

You May Also Be Interested In...

Click Here To View Or Post Comments

Comments 0 comments - Mar 1, 2002

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.